Combination Chemotherapy with Docetaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Medical Oncology
• Clinical Trials

Background:

• Docetaxel demonstrates single-agent activity in non-small cell lung cancer (NSCLC).
• Platinum compounds can enhance docetaxel efficacy.
• Carboplatin may offer similar effectiveness to cisplatin with improved tolerability.

Purpose of the Study:

• To evaluate the safety and efficacy of combining docetaxel and carboplatin chemotherapy.
• To assess this combination in patients with advanced non-small cell lung cancer (NSCLC).

Main Methods:

• A phase II study involving 30 chemotherapy-naïve patients with stage IIIB/IV NSCLC.
• Treatment regimen: docetaxel (90 mg/m²) followed by carboplatin (AUC 5 mg/ml/min) every 3 weeks for 6 cycles.
• No granulocyte colony-stimulating factor (G-CSF) was administered.

Main Results:

• Myelosuppression, primarily Grade 3/4 granulocytopenia (77%), was the main toxicity observed.
• Other toxicities, including nail disorders (27%) and mild-to-moderate non-haematological effects, were noted.
• Objective response rate was 30%, with a median time to progression of 24 weeks and median survival of 57 weeks (56% one-year survival).

Conclusions:

• The combination of docetaxel and carboplatin is well-tolerated in advanced NSCLC patients.
• This combination demonstrates significant activity and warrants further investigation.